Proceedings of the 3rd International Conference on Biological Engineering and Medical Science
DOI: 10.54254/2753-8818/23/20231066

Study of stem cells for the treatment of skin cancer

Dahui Liu

Stanstead College, Stanstead, Quebec, Canada, J0B 3E0

allenldh@outlook.com

Abstract. As no medical treatments have been found to have made any valid impacts on curing cancer yet, immunotherapy, as an epoch-making medical treatment, has been said to have the potential to cure cancer. This review paper includes trials done by the American Joint Committee on Cancer (AJCC), and clinical trials of Avelumab as means to prove the significance of stem cells and immunotherapy in treating skin cancer. According to the research, a lower disease progression was noticed. This has shown the world that the development of medicine and medical care has stepped forward and an approaching success in curing cancer in the near future.

Keywords: immunotherapy, skin cancer, stem cells, nonmelanoma skin cancer (NMSC).

1. Introduction

Pluripotent stem cells, as the type of cells that have the ability to renew and develop into other cells, have an inevitable and promising future in the field of medical science. As horrifying as cancer sounds, we have found ways to apply our knowledge of stem cells to skin cancer treatment. This has been breaking news and a really intriguing topic, as we haven't found any direct and effective methods of curing cancer. According to research, skin tumors are the most widely recognized malignancies in the US. To serve a practical purpose, this research paper reviews how immunotherapy is used and tested for the treatment of skin cancer using trials done by the AJCC and Avelumab [1].

2. CSCs: Development and formation of cancer

The cause of cancer starts with a mutation of genes. This, in turn, changes how the cells function and leads to the mutation of cells per se. And multiple subsequent mutations may cause the formation of cancer stem cells (CSCs), as they gained a biological characteristic of that of stem cells: self-renewal. Cell division in those that are cancerized becomes uncontrollable, resulting in spreading and damaging surrounding tissues, as shown in the figure below:

DOI: 10.54254/2753-8818/23/20231066



Figure 1. normal cells vs cancer cells [2].

With the ability of self-renewal being said, the other ability of differentiation was also indicated through the study from Dominique Bonnet and John E. Dick in 1997 where leukemia stem cells (LSCs) have been shown to have the abilities of differentiation and proliferation [2].

3. NMSCs

In the early stages of nonmelanoma skin cancers (NMSCs), which are among the most prevalent cancers in America, patients typically experience excellent outcomes. The majority of NMSCs can be treated with surgery and/or radiation. However, a small percentage of individuals seem to acquire a more aggressive subtype, characterized by increased resistance, which is harder to treat and where radiation and operations have had very poor results.

The cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma (BCC) are the most pervasive subtypes of NMSCs, and as indicated by the investigation of Ann W. Silk, and so forth., they regularly have better visualizations. The most regular reason for NMSVs is openness to bright (UV) radiation, in spite of the way that subtype-explicit etiological variables for NMSCs have been found, for example, the infection Merkel cell polyomavirus (MCPyV) in Merkel cell carcinomas (MCC) that are infection positive.

The cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma (BCC) are the most pervasive subtypes of NMSCs, and as indicated by the investigation of Ann W. Silk, and so forth., they regularly have better visualizations. The most regular reason for NMSVs is openness to bright (UV) radiation, in spite of the way that subtype-explicit etiological variables for NMSCs have been found, for example, the infection Merkel cell polyomavirus (MCPyV) in Merkel cell carcinomas (MCC) that are infection positive [3].

4. Treatment: Immunotherapy

For a subset of patients with state of the art MCC, reactions to Immunogenetics and Cell Immunology (ICIs) have been viewed as stronger and offer delayed endurance. When the guideline was published, the FDA had approved two ICIs for the treatment of MCC: pembrolizumab and avelumab. The list of ICIs that were approved by the FDA for MCC, CSCC, and BCC at the time the rule was distributed can be found in the figure below.

DOI: 10.54254/2753-8818/23/20231066



Figure 2. Guidelines of MCC, CSCC and BCC [4].

There is currently no evidence to suggest that one ICI is superior to the other for patients. Patients chose diversely across preliminaries might be the reason for differences in revealed reaction rates. In addition, as the Safe biomarkers for response to ICIs for the MCC portion analyzed, the Lance Merkel 200 and Component 017 assessments conducted exploratory analyses on a number of biomarkers, including TMB, PD-L1 enunciation, malignant growth entering lymphocyte (till) densities, and development contamination status. In light of their low judicious power, the name signs didn't show a prerequisite for companion suggestive testing, despite the way that different biomarkers have been associated with designs toward additional created objective response rate (ORR), development free perseverance (PFS), and as a rule (working framework).

In Walk 2017, the FDA allowed Avelumab to be used to treat metastatic MCC. The accelerated opportunity relied upon the general stage II open-mark research Spear Merkel 200 (NCT02155647). 204 patients were enrolled, and they were parted into two gatherings: With the exception of adjuvant chemotherapy administered with no clinically detectable or metastatic disease less than six months prior to the start of the study, patients with metastatic or distantly recurrent MCC were included in Part B. Section An included patients with metastatic MCC whose sickness had advanced subsequent to getting first-line chemotherapy. Patients in the two gatherings got avelumab at a measurements of 10 mg/kg intravenously (IV) like clockwork until sickness movement or extreme unfriendly occasions (AEs) happened. Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1) evaluated ORR as the primary objective. The viability results from 88 patients To some extent A filled in as the establishment for endorsement once the last persistent selected had completed a year follow-up (Table 2). The ORR was kept up with over a more drawn out follow-up period (middle 40.8 months), with 10 patients (11.4%) encountering a total reaction (CR) and 19 patients (21.6%) encountering a halfway reaction (PR). At 44 months of follow-up (as of May 2019), the middle term of reaction (DOR) was 40.5 months (95% CI 18 to not respectable [NE]) and the operating system was 12.6 months (95% CI 7.5 to 17.1). By week 7, twenty of the 29 patients had confirmed responses, and by week 13, 27 had a response. Quick response was associated with additional created perseverance. The 20 patients who had an objective reaction at 7 weeks had an essentially higher 18-month endurance likelihood (90%, 95% CI 65.6% to 97.4%) than

DOI: 10.54254/2753-8818/23/20231066

the individuals who had no true reaction (26.2%, 95% CI 15.7% to 37.8%). Patients with objective responses had significantly different odds of survival at 13 weeks. At one year, two years, and three years, the PFS rates of the 88 patients in part A were respectively 30 percent (95 percent confidence interval (CI) 21 percent to 41%), 26 percent (95 percent CI 17% to 36%), and 21 percent (95 percent CI 12% to 32%). Patients' personal satisfaction has likewise been found to work on because of getting avelumab treatment.

Essential examinations in 116 patients with a middle development of 21.2 months (range 14.9 to 36.6) revealed an ORR of 39.7%, with 16.4% (n=19) experiencing a CR and 23.3% (n=27) experiencing a PR, according to limited extent B of the Spear Merkel 200 review. Likewise, the survey uncovered a solid response speed of 30.2% (95% CI 22.0% to 39.4%), or a CR or PR that persevered under a half year. The middle chance to reaction for patients was 6.1 weeks, with a scope of 90 days to 90 days for reactions in most of patients. 5 – 36). The 95% confidence interval (CI) for the median PFS was 4.1 months. The 6-and year operating system rates were 75% (95% CI 66% to 82%) and 60% (95% CI half to 68%), separately, and the middle operating system was 20.3 months (95% CI 12.4 to NE) [5].

The wellbeing information from Spear Merkel 200 exhibit that patients with MCC by and large endure avelumab. At three year follow-up examinations, 68 patients (77.3 percent) in the section An arm detailed treatment-related unfriendly occasions (TRAEs) of any grade, with 10 patients (11.4 percent) revealing TRAEs of grade 3. There were resistant related antagonistic occasions (irAEs) in 19 patients (21.6%), with 4 patients (4.5%) encountering grade 3 irAEs. Although there were no deaths related to treatment, TRAEs forced 8 patients—or 9.1%—to stop receiving treatment. The wellbeing profiles of the part B arm were comparative, with any-grade TRAEs happening in 94 of 116 patients (or 81%); Twenty patients, or 17.2%, encountered a TRAE of grade 3, one patient encountered a TRAE of grade 4 (dermatitis psoriasis), and fourteen patients, or 12.1%, quit getting treatment. 35 patients (30.2%) had poison levels that were distinguished as irAEs, and seven patients (6%) had irAEs of a grade [6].

5. Future prospects

Immunotherapy has a bright future as a cancer treatment strategy. It is anticipated to keep developing and getting better as scientists learn more about the intricate interactions between the immune system and cancer cells. Numerous cancers have already responded admirably to immunotherapy, and current research aims to extend its efficacy to additional cancer types.

With its existing challenges, the future beholds still looks promising. Since it is a treatment based on patients' immune systems, and has less side effects than other traditional cancer treatments do, such as chemotherapy, or radiotherapy. Other than tumorous diseases, immunotherapy has also shown magnificent effects on non-tumorous diseases like HIV, autoimmune disorder, etc[7].

In addition, immunotherapy can also be personalized treatment for patients through customized treatment programs. For example, customized CAR-T cells can be designed according to the specific disease situation of the patient, thus effectively improving the success rate of treatment. The advantage of this approach is the precise identification and attack of cancer cells, and symptomatic treatment.

There are still issues to resolve, though. The emergence of immunotherapy resistance over time is one of the main worries. The long-term efficacy of treatment is constrained by the ability of cancer cells to adapt and find ways to evade immune attack. Strategies to get past this resistance and improve response durability are actively being researched.

Additionally, more individualized immunotherapy strategies are required. Finding predictive biomarkers that can direct treatment choices is essential because not all patients respond the same to the same course of treatment. Precision medicine and genomic profiling developments should make it easier to customize immunotherapies for specific patients, which will boost their effectiveness.

Overall, the future of immunotherapy appears bright as ongoing efforts are directed towards overcoming obstacles, enhancing response rates, and extending its use across various cancer types. The field will advance through continued research and innovation, possibly revolutionizing cancer treatment and enhancing patient outcomes.

The advantages of immunotherapy can be summarized as: being able to shrink late tumors that are already metastatic and/or resistant, lasting for a long time and even produces "supper survivors", and

DOI: 10.54254/2753-8818/23/20231066

having a low proportion of serious toxic and side effects. Although it has only been a few years, this has completely altered our concepts towards scientific researches of cancer and cancer treatments. As a cancer treatment per se, it establishes a firm base for the future in the field of medicine. However, we should not be satisfied with the present situation as the number of patients responding to immunotherapy is still in the minority. In 2020s, we embrace the 2.0 era for immunotherapy. Our goal is to continue to understand cancer through basic and clinical research, and to overcome limitations and shortcomings of current therapies.

The development of immunotherapy is a "prairie fire", bringing a lot of new hope to patients. Other than skin cancer as talked above in this paper, it is more and more widely used in lung cancer, gastric cancer, esophageal cancer, head and neck cancer and other cancers at present, which has improved the five-year survival rate of many cancer types.

Immunotherapies offer great promise for combating cancer. Adoptive cell therapy now has good results in a variety of cancers, and faster clinical progress. At the same time, more and more studies are combining this therapy with existing traditional therapies in order to achieve greater breakthroughs in cancer treatment. It is believed that with the development of technology and innovative therapies, the individual pain and medical costs caused by cancer will be greatly reduced in the coming decades[8].

6. Conclusion

Immunotherapy is a particularly effective approach against skin cancer. Although radiation and surgery can resolve most underlying early-stage skin cancers, cancer cells that have mutated or spread require immunotherapy, as the research listed above has shown the noticeable effectiveness of immunotherapy compared to other methods.

However, due to various reasons, the universality of immunotherapy is limited. In the future of our human development, immunotherapy should become common. This will not only reduce the mortality rate due to cancer, but also reduce the threat of cancer to people, as cancer is now recognized as the most terrifying disease by people around the globe. It is believed that immunotherapy will be of great use to human beings, and the generalization of such medical treatment will soon be achieved.

References

[1] Brandt, M. W., & Moore, C. L. (2019). Nonmelanoma Skin Cancer. Facial Plastic Surgery Clinics of North America, 27(1), 1–13. https://doi.org/10.1016/j.fsc.2018.08.001

[2] Zhang, Y., & Zhang, Z. (2020). The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cellular & Molecular Immunology, 17(8), 807–821. https://doi.org/10.1038/s41423-020-0488-6

[3] Ebrahimi, A., Ahmadi, H., Pourfraidon Ghasrodashti, Z., Tanide, N., Shahriarirad, R., Erfani, A., Ranjbar, K., & Ashkani-Esfahani, S. (2021, December 1). Therapeutic effects of stem cells in different body systems, a novel method that is yet to gain trust: A comprehensive review. Bosnian journal of basic medical sciences. Retrieved November 28, 2022, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8554700/

[4] Guy, G. P., Thomas, C. C., Thompson, T., Watson, M., Massetti, G. M., & Richardson, L. C. (2015, June). Vital signs: Melanoma incidence and mortality trends and projections - United States, 1982-2030. MMWR. Morbidity and mortality weekly report. Retrieved December 18, 2022, from https://pubmed.ncbi.nlm.nih.gov/26042651/

[5] Palmeri, M., Mehnert, J., Silk, A. W., Jabbour, S. K., Ganesan, S., Popli, P., Riedlinger, G., Stephenson, R., de Meritens, A. B., Leiser, A., Mayer, T., Chan, N., Spencer, K., Girda, E., Malhotra, J., Chan, T., Subbiah, V., & Groisberg, R. (2022, February). Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers. ESMO open. Retrieved December 2, 2022, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8717431/

DOI: 10.54254/2753-8818/23/20231066

[6] Shalhout, S. Z., Emerick, K. S., Kaufman, H. L., & Miller, D. M. (2021, August). Immunotherapy for non-melanoma skin cancer. Current oncology reports. Retrieved February 13, 2023, from https://pubmed.ncbi.nlm.nih.gov/34448958/

[7] Silk, A. W., Barker, C. A., Bhatia, S., Bollin, K. B., Chandra, S., Eroglu, Z., Gastman, B. R., Kendra, K. L., Kluger, H., Lipson, E. J., Madden, K., Miller, D. M., Nghiem, P., Pavlick, A. C., Puzanov, I., Rabinowits, G., Ruiz, E. S., Sondak, V. K., Tavss, E. A., … Brownell, I. (2022, July). Society for immunotherapy of cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer. Journal for immunotherapy of cancer. Retrieved December 18, 2022, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9341183/#